Shares of Ardent Health, Inc. (NYSE:ARDT - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the twelve research firms that are covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and nine have issued a buy recommendation on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $19.3273.
ARDT has been the topic of several analyst reports. JPMorgan Chase & Co. cut their price target on shares of Ardent Health from $18.00 to $15.00 and set a "neutral" rating on the stock in a report on Monday, August 11th. Bank of America lowered shares of Ardent Health from a "neutral" rating to an "underperform" rating and cut their price target for the stock from $15.50 to $14.60 in a report on Wednesday, July 16th. KeyCorp cut their price target on shares of Ardent Health from $24.00 to $20.00 and set an "overweight" rating on the stock in a report on Thursday, August 7th. UBS Group initiated coverage on shares of Ardent Health in a report on Wednesday, September 10th. They issued a "buy" rating and a $17.00 price target on the stock. Finally, Wall Street Zen raised shares of Ardent Health from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 9th.
View Our Latest Analysis on ARDT
Ardent Health Stock Performance
Shares of NYSE:ARDT opened at $14.08 on Friday. The firm has a 50 day moving average of $12.91 and a 200 day moving average of $13.04. The company has a quick ratio of 2.00, a current ratio of 2.13 and a debt-to-equity ratio of 0.66. Ardent Health has a 52 week low of $10.10 and a 52 week high of $20.72. The company has a market capitalization of $2.01 billion, a price-to-earnings ratio of 7.78, a price-to-earnings-growth ratio of 6.34 and a beta of 0.39.
Ardent Health (NYSE:ARDT - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.30 by $0.22. Ardent Health had a net margin of 4.11% and a return on equity of 16.66%. The business had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.54 billion. Ardent Health has set its FY 2025 guidance at 1.730-2.01 EPS. On average, sell-side analysts predict that Ardent Health will post 1.23 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Ardent Health
A number of large investors have recently made changes to their positions in ARDT. Rhumbline Advisers grew its holdings in shares of Ardent Health by 46.8% during the first quarter. Rhumbline Advisers now owns 24,827 shares of the company's stock valued at $341,000 after buying an additional 7,914 shares during the last quarter. Beacon Capital Management LLC purchased a new stake in shares of Ardent Health during the first quarter valued at $144,000. Allspring Global Investments Holdings LLC grew its holdings in shares of Ardent Health by 4.8% during the first quarter. Allspring Global Investments Holdings LLC now owns 817,182 shares of the company's stock valued at $10,599,000 after buying an additional 37,581 shares during the last quarter. TBH Global Asset Management LLC purchased a new stake in shares of Ardent Health during the first quarter valued at $275,000. Finally, Bank of New York Mellon Corp grew its holdings in shares of Ardent Health by 91.2% during the first quarter. Bank of New York Mellon Corp now owns 48,988 shares of the company's stock valued at $674,000 after buying an additional 23,373 shares during the last quarter.
About Ardent Health
(
Get Free Report)
Ardent Health Partners, Inc owns and operates a network of hospitals and clinics that provides a range of healthcare services in the United States. It operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. The company was founded in 2001 and is based in Brentwood, Tennessee.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Ardent Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ardent Health wasn't on the list.
While Ardent Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.